{"id":17582,"date":"2023-09-12T16:17:39","date_gmt":"2023-09-12T15:17:39","guid":{"rendered":"https:\/\/montpellier-cancer.com\/recherche\/plateformes-en-cancerologie\/plateforme-dexploration-pre-clinique-en-oncologie\/"},"modified":"2023-11-23T17:55:36","modified_gmt":"2023-11-23T16:55:36","slug":"oncology-pre-clinical-exploration-platform","status":"publish","type":"page","link":"https:\/\/montpellier-cancer.com\/en\/recherche\/plateformes-en-cancerologie\/oncology-pre-clinical-exploration-platform\/","title":{"rendered":"Preclinical Oncology Exploration Platform"},"content":{"rendered":"\n

<\/p>\n\n\n

\n
\n
\n
\n

Launched in 2021, the Pre-Clinical Exploration Platform in Oncology (so-called PEPCO) is designed to facilitate, accelerate and amplify the transfer to the clinic of innovative anti-tumour therapies.<\/p>\n

PEPCO coordinates different technical platforms at IRCM to ultimately establish an integrated structure dedicated to preclinical studies of anti-cancer therapies. In particular, PEPCO brings together the technical resources, services and expertise for the generation and in vivo use of preclinical models (including cell-line xenografts, patient-derived xenografts, or orthotopic cancer models), and their most comprehensive analysis by small animal imaging, targeted or whole-body irradiation, mass cytometry and histology.<\/p>\n

PEPCO provides both academic and private partners with a unique entry point for these services and offers optimized monitoring of projects, from their design up to the conclusions of the study.<\/p>\n<\/div>\n \n <\/div>\n

\n \"\"\n <\/div>\n <\/div>\n <\/div>\n<\/div>\n\n\n
\n
\n
\n
\n

Contacts<\/h2>\n <\/div>\n
\n
\n
\n \n <\/div>\n\n